

(12)

**EUROPEAN PATENT APPLICATION**

(21) Application number: 89122372.9

(51) Int. Cl.<sup>5</sup>: **C07D 307/79, C07D 295/135,**  
**C07D 333/54, A61K 31/34,**  
**A61K 31/38, A61K 31/40**

(22) Date of filing: 05.12.89

(30) Priority: 06.12.88 US 280759

(43) Date of publication of application:  
 13.06.90 Bulletin 90/24

(64) Designated Contracting States:  
 AT BE CH DE ES FR GB IT LI LU NL SE


(71) Applicant: **WARNER-LAMBERT COMPANY**  
 201 Tabor Road  
 Morris Plains New Jersey 07950(US)

(72) Inventor: **Horwell, David Christopher**  
 8, West Hill Foxton  
 Cambridge(GB)  
 Inventor: **Rees, David C.**  
 33, Norwich Street  
 Cambridge CB2 2JB(GB)

(74) Representative: **Mansmann, Ivo**  
 c/o Gödecke AG - Patentabteilung Postfach  
 569 Mooswaldallee 1-9  
 D-7800 Freiburg(DE)

(54) 2-Amino-4 or 5-methoxycyclohexyl amides useful as analgesics.

(57) The invention concerns a series of novel 2-amino-monomethoxycyclohexyl amides of the general formula



**EP 0 372 466 A2**

having analgesic and neuroprotective activity. The compounds bind selectively to the kappa opioid receptor. Pharmaceutical compositions containing the compounds, methods of using them, and processes for preparing them are also disclosed.

## 2-AMINO-4 OR 5 METHOXYCYCLOHEXYL AMIDES USEFUL AS ANALGESICS

## BACKGROUND OF THE INVENTION

The search for strong analgesics which also possess minimal potential for dependency has been among the highest priority efforts in pharmaceutical research. These research efforts have, to a great extent, involved chemical modification of the opiate structure and the discovery of novel compounds which possess morphine-like activity.

The concept of multiple opioid receptors has been supported by studies with nalorphine and a series of benzomorphans which display unusual pharmacological properties dissimilar from morphine, yet blocked by the opioid antagonists. [See, for example, W. R. Martin, et al., J. Pharmacol. Exp. Ther., 197: 517-532 (1976).]

The existence of multiple types of opioid receptors is of importance because it suggests the possibility of separating the desirable analgesic and psychotherapeutic effects of a drug compound from the undesirable abuse potential or habituating effects.

United States Patent 4,098,904 discloses certain cis- and trans-N-(2-aminocycloaliphatic) benzamide compounds having analgesic activity.

United States Patent 4,145,435 describes certain 2-amino-cycloaliphatic amide compounds as analgesics. In particular, trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide is reported to possess selective kappa agonist activity, and therefore, to possess analgesic activity without attendant dependence liability. [See P. V. Vonvoigtlander, et al., J. Pharmacol. Exp. Ther., 224: 7-12 (1983).]

United States Patent 4,212,878 discloses certain N-[(4-mono- or di-oxygen-group-substituted-1-aminocyclohex-1-yl)methyl]benzeneacetamides, particularly trans-2-(3,4-dichlorophenyl)-N-[[8-(1-pyrrolidinyl)-1,4-dioxaspiro[4.5]dec-8-yl)methyl]acetamide having analgesic properties.

United States Patent 4,359,476 and its continuation-in-part 4,460,600 disclose certain N-[2-amino(oxy or thio group) substituted cycloaliphatic]benzeneacetamide and -benzamide compounds having the oxy- or thio group substituents on a cycloaliphatic ring carbon adjacent to either of the nitrogen-bearing carbon atoms of the cycloaliphatic ring. These compounds, having analgesic activity are typified by 4-bromo-N-[3-methoxy-2-(1-pyrrolidinyl)cyclohexyl]-N-methylbenzamide.

United States Patent 4,598,087 and its divisional, United States Patent 4,677,122, disclose certain oxy- or thioacetamides of trans-1,2-diaminocyclohexane having analgesic activity. These compounds are typified by trans-2-(2,3-dichlorophenoxy)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]acetamide.

United States Patent 4,656,182 discloses certain trans-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzo[b]thiophene acetamides having analgesic activity.

United States Patent 4,663,343 discloses certain trans-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-naphthalenyloxy- and naphthalenylthioacetamides having analgesic activity.

United States Patent 4,737,493 discloses certain substituted phenoxy-, 1-, and 2-naphthalenyloxy, indenyl-, indolyl-, benzofuranyl-, and benzo[b]thiophenylcarboxamides of 7,8-(substituted-diamino)-1-oxaspiro[4.5]decanes useful as analgesic agents.


United States Patent 4,463,013 discloses certain oxygen substituted amino-cyclohexyl-benzeneacetamides as diuretics.

United States Patent 4,438,130 discloses certain mono-oxa-, thiaspiro-cyclic-benzeneacetamide and benzamide compounds useful as analgesics.

## SUMMARY OF THE INVENTION

The invention relates to a novel series of 2-amino-4 or -5-monomethoxycyclohexyl amides which possess selective kappa receptor analgesic activity. The compounds show a surprising increase in activity in the nociceptive assay of the rat paw pressure test of M. B. Tyers, Brit. J. Pharmacol., 69: 503-512 (1980) when compared with compounds known in the art.

The invention covers novel amides of formula



10 and the pharmaceutically acceptable acid addition salts thereof wherein X, R<sub>1</sub>, R<sub>2</sub>, and A are as defined herein below.


The invention also includes pharmaceutical compositions comprising an analgesically effective amount of the above compound in admixture with a pharmaceutically acceptable carrier or excipient and a method of treating pain in a patient suffering therefrom comprising administering to said patient the pharmaceutical composition in unit dosage form.

15 The invention further includes pharmaceutical compositions comprised of a neuroprotective amount of the above compound in admixture with a pharmaceutically acceptable carrier or excipient as well as a method of treating stroke and/or cerebral ischemia in a patient suffering therefrom.

20 The invention further includes the use of compounds of formula I above for the preparation of pharmaceutical compositions for treating pain and stroke as well as methods for preparing the compounds of formula I above.

#### 25 DETAILED DESCRIPTION

The compounds of the present invention are represented by formula



wherein the two nitrogen atoms attached to the cyclohexane moiety are trans to one another;



X is CH<sub>2</sub> or direct bond,

R<sub>1</sub> is methyl,

R<sub>2</sub> is selected from the group consisting of:

hydrogen,


alkyl of from one to six carbon atoms,



-CH<sub>2</sub>H = CR<sub>3</sub>R<sub>4</sub>,

-CH<sub>2</sub>C≡R<sub>3</sub>,

-2- or 3-thienyl, or



5

wherein  $\text{R}_3$  and  $\text{R}_4$  are each independently hydrogen or methyl,

$\text{R}_5$  is selected from the group consisting of:

hydrogen,

10

fluorine,

chlorine,


bromine,

lower alkyl, and

lower alkoxy;

15

or  $\text{R}_1$  and  $\text{R}_2$  may be taken together with the nitrogen atom to which they are attached to form a ring




20


wherein  $n$  is an integer of from 3 to 8;

A is selected from the group consisting of:


25



30



35



40

phenyl,

phenyl substituted with from one to four halogen atoms,

45

phenyl substituted with one or two alkyl groups of from one to four carbon atoms,


phenyl substituted with one or two alkoxy groups of from one to four carbon atoms, or

phenyl substituted with one or two alkyl groups of from one to four carbon atoms and one or two halogen atoms; or

a pharmaceutically acceptable acid addition salt thereof.

50

Preferred compounds of the present invention as those of formula I wherein  $\text{X}$  is  $\text{CH}_2$  and A is



55

Other preferred compounds of the present invention are those of formula I wherein  $\text{X}$  is a direct bond

and A is



15 Particularly preferred compounds of the present invention are those of formula I wherein X is CH<sub>2</sub>, A is




25 and R<sub>1</sub> and R<sub>2</sub> may be taken together with the nitrogen to which they are attached to form a ring



wherein n is an integer of from 3 to 8, preferably 4.


35 The most preferred compounds of the present invention are selected from the list consisting of:  
 (±)-(1α,2β,4α)-N-methyl-N-[4-methoxy-2-(1-pyrrolidinyl) cyclohexyl]-4-benzofuranacetamide,  
 (±)-(1α,2β,4α)-N-methyl-N-[4-methoxy-2-(1-pyrrolidinyl) cyclohexyl]-4-benzofuranacetamide,  
 (±)-(1α,2β,5β)-N-methyl-N-[5-methoxy-2-(1-pyrrolidinyl) cyclohexyl]-4-benzofuranacetamide,  
 (±)-(1α,2β,5β)-N-methyl-N-[5-methoxy-2-(1-pyrrolidinyl) cyclohexyl]-4-benzofuranacetamide,  
 40 (±)-(1α,2β,4α)-N-methyl-N-[4-methoxy-2-(1-pyrrolidinyl) cyclohexyl]-9H-fluorene-9-carboxamide, and  
 (±)-(1α,2β,5β)-N-methyl-N-[5-methoxy-2-(1-pyrrolidinyl) cyclohexyl]-9H-fluorene-9-carboxamide.

A method for preparing compounds of formula I wherein A is




50 which comprises reacting an amine compound of formula


55




10 wherein  $R_1$  and  $R_2$  are as defined above with  $A-X-CH_2COB$  wherein B is -Cl, -OH, -OC<sub>6</sub>F<sub>5</sub> or




20 and, if desired, converting the product to a pharmaceutically acceptable acid addition salt thereof.  
A method for preparing compounds of formula I wherein A is




35 which comprises reacting an amine compound of formula



45 wherein  $R_1$  and  $R_2$  are as defined above with



55 wherein B is -OH, -Cl, or



5

or  $\text{OC}_6\text{F}_5$  and, if desired, converting the product to a pharmaceutically acceptable salt thereof.

The compounds of the present invention include solvates, hydrates, and pharmaceutically acceptable acid addition salts of the basic compounds of formula I above.

10 By virtue of the basic nitrogen on the cyclohexane moiety, pharmaceutically acceptable salts of compounds of the present invention may be prepared by reaction with appropriate acids. Suitable acids for the formation of pharmaceutically acceptable salts of the compounds of this invention form a class well known to practitioners of the pharmaceutical formulation arts (cf. S. M. Berge, et al., "Pharmaceutical Salts" in *J. Pharm. Sci.*, 66: 1-19 (1977)), and include such acids as hydrochloric, hydrobromic, hydriodic, sulfuric, 15 nitric, phosphoric, acetic, benzoic, citric, maleic, tartaric, succinic, gluconic, ascorbic, sulphamic, oxalic, pamoic, methanesulfonic, benzenesulfonic, ethanesulfonic, hydroxyethanesulfonic, and related acids and mixtures thereof.

The salts are generally prepared by reacting the free base with one equivalent of the desired acid in an appropriate unreactive solvent, followed by collection of the salt by filtration or recovery upon removal of the 20 solvent. The free base may be regenerated, if desired, by reaction of the salt with one equivalent of a base such as sodium hydroxide, sodium bicarbonate, sodium carbonate, and the like. The salts may differ from the free base form of compounds of this invention in properties such as melting point and solubility in polar solvents, but are otherwise considered equivalent for the purposes of this invention.

The compounds of the present invention contain three or more asymmetric carbon atoms. The 25 compounds exist in various stereo- and regio-isomeric forms and mixtures thereof. The present invention contemplates all stereo- and regio-isomeric forms of the compounds of formula I above. Both the (+) and (-) and the ( $\pm$ ) are contemplated by the invention.

The individual stereo compounds or enantiomers are obtained, if desired, from a mixture of different forms by known methods of resolution such as the formation of diastereomers followed by recrystallization.

30 The compounds of the present invention possess significant analgesic activity with the potential for minimum dependence liability due to their selective kappa opioid receptor properties. In addition to producing analgesia, compounds which are selective kappa agonists, such as the compounds of this invention, also cause opioid receptor-mediated sedation, diuresis, and corticosteroid elevation. Accordingly, the compounds of this invention may also be useful as diuretics and psychotherapeutic agents as well as 35 analgesics.

The compounds of the present invention also have application in congestive heart failure, advanced hepatic cirrhosis, nephrotic syndrome, chronic renal failure, trauma associated with surgery, emotional and physical stress, endocrine disorders, syndrome of inappropriate antidiuretic hormone secretion and therapy 40 with certain pharmacologic drug agents such as certain sulphonyl ureas, certain biguanides such as phenformin and metformin, clofibrate, certain tricycles such as carbamazepine, amitriptyline, thiothixene, fluphenazine and thioridazine, certain antineoplastic agents, certain analgesics and certain natriuretic diuretics.


The compounds of the present invention also have neuroprotective indications. As such they are useful 45 in the treatment of stroke and the treatment of cerebral ischemia (P. F. Von Voightlander in *Brain Research* 435: 174-180 (1987)) and A. H. Tang, et al. in *Brain Research* 403: 52-57 (1987)).

Representative compounds of the present invention demonstrate positive activity in standard laboratory analgesic tests in animals such as mice. The  $\text{MPE}_{50}$  doses for several representative compounds of this invention in the standard rat paw pressure analgesia test M. B. Tyers, *Brit. J. Pharmacol.*, (1980), 69: 503-512 are presented in Table I below, the last column.

50

55

TABLE I



Compound Number	Structure (Position of OMe)	R	Opioid Binding (K <sub>i</sub> nM)			Rat Paw Pressure MPE <sub>50</sub> (mg/kg) I.V.
			kappa	mu	mu/k	
10	4-β	R <sup>1</sup>	7.1 ± 4	3300 ± 1900	465	0.07
5	4-α	R <sub>1</sub>	22 ± 6	2200 ± 200	100	0.07
6	5-β	R <sup>1</sup>	135 ± 30	11000 ± 4800	81	5.6
7	5-α	R <sup>1</sup>	24 ± 4	4300 ± 400	179	1.5
8	4-α	R <sup>2</sup>	0.84 ± 0.9	28 ± 1.3	33	-
9	5-β	R <sup>2</sup>	6.7 ± 1.3	2130 ± 176	318	>1

K<sub>i</sub> values represent the mean ± (standard error of the mean) from concentration-response curves performed in triplicate from each of at least two separate experiments.

MPE<sub>50</sub> values represent the dose required to produce 50% of the maximum possible analgesic effect. They are derived from a single experiment with six animals per dose level.

Representative compounds of the present invention were also tested *in vitro* to determine the extent of opioid receptor binding, and were found to bind selectively to the kappa opioid receptor site with evidence of little or no binding to the mu or delta opioid receptors.

Measurement of the kappa opioid receptor binding activity of compounds of the present invention was made by the following method. Guinea pig brain homogenates were prepared fresh daily utilizing the method of Gillan et al. *Br. J. Pharmacol.* (1980) 70: 481-490.

The binding of tritiated etorphine to brain homogenates was measured in the presence of unlabeled competitor compounds of the present invention with 200 nanomolar D-alanine-D-leucine-enkephalin (acronym DADLE) and 200 nanomolar D-ala-MePheGly-ol-enkephalin (acronym DAGO) added to saturate



the delta and mu opioid receptors, respectively. The reaction was terminated by rapid filtration and the radioactivity bound to the filters counted by liquid scintillation spectrophotometry.

Measurement of the mu and delta opioid receptor binding activity of the compounds of this invention was made by the following method. Guinea pig brain homogenates were freshly prepared daily by the method of Gillan, et al., cited above.

Homogenates were incubated for 150 minutes at 0° C with either tritiated DAGO to measure mu receptor binding activity, or with tritiated DADLE in the presence of a ten-fold excess of unlabeled DAGO to measure delta opioid receptor binding. Nonspecific binding was determined in the presence of 10<sup>-6</sup> molar DAGO and 10<sup>-6</sup> molar DADLE.

Reactions were terminated by rapid filtration and the radioactivity bound to the filters counted by liquid scintillation spectrophotometry.

The data were analyzed by the methods of Scatchard, Ann. N.Y. Acad. Sci., 51: 660-672 (1949) and Hill, J. Physiol., 40: IV-VIII (1910). The inhibition of the binding of tritiated etorphine, DAGO and DADLE by cold ligands was determined from the regression of log percentage inhibition of specific binding or log concentration of cold ligand. The inhibition constant, K<sub>i</sub>, was calculated from the equation:

$$K_i = \frac{IC_{50}}{1 + [L]/K_D}$$


where [L] is the concentration of the labeled ligand and K<sub>D</sub> is the equilibrium dissociation constant.

Scheme I below illustrates chemical synthesis of the compounds of the present invention. All compounds are racemic mixtures. They are prepared by epoxidizing 4-methoxycyclohexene [Gogek, Moir and Purves, Can. J. Chem., 29: 946 (1951)] by the action of m-chloroperbenzoic acid in dichloromethane to yield the 4-methoxycyclohexene epoxides (1). Reaction of (1) with N-benzylmethylamine in alcohol yields a mixture of three isomeric amino alcohols (2). This mixture of amino alcohols, (2), is treated with methanesulphonyl chloride and subsequently with pyrrolidine to yield a mixture of N-benzylamines, (3). This mixture of N-benzylamines, (3), is dissolved in alcohol and then catalytically hydrogenated to form a mixture of diamines (4). This mixture of diamines, (4), may then be reacted with an ester of 9-fluorenylcarboxylic acid to form the desired product which may then be separated by known means.

Alternatively, the mixture of diamines (4), may be reacted with 4-benzofuranacetyl chloride to yield a mixture of isomers of the desired product which may be separated by known means.

(10) was prepared from the epoxides (1) by an analogous procedure to that described above for (5), (6), and (7) except that pyrrolidine was used instead of N-benzylmethylamine and vice versa.

SCHEME I  
(all compounds are racemic)



SCHEME I (cont'd)  
(all compounds are racemic)

5

10

15

20

25


30

35

40

45

50



Compounds of the present invention and/or their nontoxic, pharmaceutically acceptable salts may be administered to mammals orally in combination with conventional compatible carriers in solid or in liquid form. These oral pharmaceutical compositions may contain conventional ingredients such as binding agents selected from syrups, acacia, gelatin, sorbitol, tragacanth, polyvinylpyrrolidone, and mixtures thereof. The

compositions may further include fillers such as lactose, mannitols, starch, calcium phosphate, sorbitol, methylcellulose, and mixtures thereof.

These oral compositions may also contain lubricants such as magnesium stearate, high molecular weight polymers such as polyethylene glycol, high molecular weight fatty acids such as stearic acid, silica, or agents to facilitate disintegration of the solid formulation such as starch, and wetting agents such as sodium lauryl sulfate.

The solid oral compositions may take any convenient form such as tablets, lozenges, capsules, or dry powders which may be reconstituted with water or other suitable liquid prior to administration.

Liquid form pharmaceutical compositions may take the form of solutions, suspensions, or emulsions. The liquid forms may contain flavorants, sweeteners, and/or preservatives such as alkyl p-hydroxybenzoates. They may further contain suspending agents such as sorbitol, glucose, or other sugar syrups, methyl-, hydroxymethyl- or carboxymethylcellulose, and gelatin, emulsifying agents such as lecithin or sorbitol monooleate, and conventional thickening agents.

Liquid compositions may optionally be encapsulated in, for example, gelatin capsules in an effective amount.

The compounds of the invention may also be administered to mammals rectally in the form of suppositories. For preparing suppositories, a low-melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously in the melt. The mixture is then poured into convenient sized molds and allowed to cool and solidify.

Preferably, the pharmaceutical compositions of this invention are in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate amounts of the active component. The unit doses can be a packaged preparation with the package containing discrete quantities of the preparation. For example, the package may take the form of packaged tablets, capsules, and powders in envelopes, vials, or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself or can be the appropriate number of any of these in package form.

The quantity of active compound in a unit dose of preparation may be varied or adjusted from about 0.01 mg to about 350 mg according to the particular application and the potency of the active ingredient.

When employed systematically in therapeutic use as analgesic agents in the pharmaceutical method of this invention, the compounds are administered at doses of from about 0.0001 mg to about 2.0 mg of active compound per kilogram of the recipient.

The following examples are provided to enable one skilled in the art to practice the present invention. These examples are not intended in any way to limit the scope of the invention but are intended as illustrative thereof.

#### EXAMPLE 1

##### 4-Methoxycyclohexane epoxide (1)

m-Chloroperoxybenzoic acid (3.5 g, 20 mmol) in 1:1 dichloromethane-carbon tetrachloride (70 ml) was added over 25 minutes to a stirred solution of 4-methoxycyclohexene (2.0 g, 18 mmol) in carbon tetrachloride (10 ml) at  $-5^{\circ}\text{C}$ . After five hours the mixture was allowed to warm to room temperature and after two hours the slurry was filtered. The filtrate was washed with 5% aqueous sodium bisulphite (40 ml) then saturated aqueous sodium carbonate (2 x 40 ml). The resulting solution was dried ( $\text{K}_2\text{CO}_3$ ) and distilled using a vigreux column at atmospheric pressure to give the epoxides (1) as a mixture of two diastereoisomers (1.0 g, 7.8 mmol), 43%), bp  $175\text{--}176^{\circ}\text{C}$  (760 mm Hg); i.r. (neat) 2938, 1104  $\text{cm}^{-1}$ ;  $\delta$  - ( $\text{CDCl}_3$ , 300  $\text{MHz}$ ) 3.22 (1H,m); 3.24 (s) and 3.22 (s) together (3H); 3.05 (2H,m), 2.3-1.2 (6H,m);  $m/e$  ( $\text{EI}^+$ ) 129 (11%), 111 (35%), 97 (65%), 58 (100%);  
Anal.  $\text{C}_7\text{H}_{12}\text{O}_2$  requires C, 65.60; H, 9.44.  
Found C, 65.57; H, 9.60%.

#### EXAMPLE 2

## Amino alcohols (2)

The epoxides (1) (2.0 g, 15.6 mmol) and N-benzylmethylamine (3.0 g, 25 mmol) were dissolved in propan-2-ol (10 ml) and heated under reflux for 20 hours. The resulting solution was distilled to give the amino alcohols (2) as a mixture of three isomers (3.2 g, 13 mmol, 83%), bp 133-134 °C/ 0.05 mbar; i.r. (neat) 3460, 2939, 2866  $\text{cm}^{-1}$ ;  $\delta$  ( $\text{CDCl}_3$ ,  $\text{D}_2\text{O}$ ) 7.3 (5H,m); 4.0-2.7 (7H,m, strong s at 3.36, 3.30, 3.29); 2.4-1.2 (10H,m, strong s at 2.19, 2.18, 2.15); m/e ( $\text{EI}^+$ ) 249 (10%), 218 (8%), 190 (100%); Anal.  $\text{C}_{15}\text{H}_{23}\text{NO}_2$  requires C, 72.25; H, 9.30; N, 5.62.

Found C, 72.13; H, 9.22; N, 5.56%.  $^1\text{H}$  nmr spectra of the individual isomers were obtained after separation by silica gel chromatography using 20:1 dichloromethane-methanol.  $\delta$  ( $\text{CDCl}_3$ ,  $\text{D}_2\text{O}$ ) Isomer A: 7.24 (5H,m), 3.61 (1H,d,J=14); 3.45 (1H,J=14); 3.43 (1H,m); 3.36 (3H,s); 3.18 (1H,m); 2.36 (1H,m); 2.19 (3H,s); 2.27-1.99 (3H,m); 1.22 (3H,m). Isomer B: 7.28 (5H,m); 3.70 (1H,d,J=15 Hz); 3.65 (1H,m); 3.45 (1H,m); 3.44 (1H,d,J=15 Hz); 3.30 (3H,s); 2.83 (1H,m); 2.15 (3H,s); 2.20-1.85 (3H,m); 1.60 (1H,m); 1.30 (2H,m). Isomer C: 7.28 (5H,m); 3.79 (1H,m); 3.74 (1H,d,J=15 Hz); 3.55 (1H,m); 3.45 (1H,d,J=15 Hz); 3.29 (3H,s); 2.42 (2H,m); 2.18(3H,s); 2.05 (1H,m); 1.55 (2H,m); 1.30 (2H,m).

## EXAMPLE 3

## N-Benzyl diamines (3)

The diastereoisomeric mixture of amino alcohols (2) (8.0 g, 32 mmol) was dissolved in dichloromethane (105 ml) and triethylamine (7.1 ml), cooled to -10 °C, and treated with methanesulphonyl chloride (2.7 ml, 35 mmol) dropwise such that the temperature remained below -5 °C. After 1.5 hours the mixture was concentrated in vacuo to a volume of 20 ml and treated with pyrrolidine (22 ml, 260 mmol) under reflux for 1.5 hours. The resulting mixture was poured into aqueous sodium carbonate (700 ml) and extracted with dichloromethane (3 x 100 ml) to give, after concentration, an orange oil (15 g) which was distilled to give the N-benzyl diamines (3) as a mixture of three (racemic) isomers (9.3 g, 31 mmol, 97%); bp 122-155 °C/0.2 mbar; i.r. (neat) 2936, 2791  $\text{cm}^{-1}$ ; m/e ( $\text{EI}^+$ ) 303 (5%); 287 (10%), 270 (10%), 84 (100%);  $\delta$  ( $\text{CDCl}_3$ ,  $\text{D}_2\text{O}$ , 300 MHz); 7.30 (5H,m); 3.65 (2H,s); 3.75-3.50 (1H,m); 3.36 (s) and 3.32 (s) and 3.29 (s) together are (3H); 2.19 (s) and 2.17 (s) and 2.15 (s) together are (3H); 3.10-1.00 (16H,m). Anal.  $\text{C}_{19}\text{H}_{30}\text{N}_2\text{O} \cdot 0.33\text{H}_2\text{O}$  requires C, 74.00; H, 10.02; N, 9.08. Found C, 73.97; H, 9.78; N, 8.82%.

## EXAMPLE 4

## Diamines (4)

The N-benzyl diamines (3) (3.5 g, 12 mmol) were dissolved in ethanol (50 ml) and treated with 20% palladium hydroxide on carbon (0.94 g) and hydrogen at 50 psi at 60 °C for two hours. The mixture was filtered through kieselguhr and distilled to give the diamines (4) as a mixture of three (racemic) isomers (1.4 g, 6.6 mmol, 55%); bp 84-85 °C/0.3 mbar; i.r. (neat) 3402, 2942  $\text{cm}^{-1}$ ; m/e ( $\text{EI}^+$ ) 197 (5%), 180 (10%), 84 (100%);  $\delta$  ( $\text{CDCl}_3$ ,  $\text{D}_2\text{O}$ , 300 MHz), 3.36 (s) and 3.31 (s) and 3.28 (s) together are (3H); 2.38 (s) and 2.37 (s) together are (3H); 3.7 (1H,m); 2.8-0.9 (17H,m). An analytically pure sample was obtained by treating (4) (212 mg, 1.0 mmol) with p-toluene sulphonic acid (190 mg, 1.0 mmol) in propan-2-ol (1 ml) to give a white solid which was recrystallized from propan-2-ol/ diethyl ether to give the mono-p-toluenesulphonate salt (200 mg, 0.50 mmol, 50%), mp 120-136 °C. Anal.  $\text{C}_{12}\text{H}_{24}\text{N}_2\text{O} \cdot \text{C}_7\text{H}_6\text{SO}_3$  requires C, 59.35; H, 8.39; N, 7.29; S, 8.34. Found C, 58.95; H, 8.24; N, 6.99; S, 8.42%.

## EXAMPLE 5

( $\pm$ )-(1 $\alpha$ ,2 $\beta$ ,4 $\alpha$ )-N-[4-methoxy-2-(1-pyrrolidinyl)cyclohexyl]-N-methyl-4-benzofuranacetamide (5);  
 5 ( $\pm$ )-(1 $\alpha$ ,2 $\beta$ ,5 $\beta$ )-N-[5-methoxy-2-(1-pyrrolidinyl)cyclohexyl]-N-methyl-4-benzofuranacetamide (6);  
 ( $\pm$ )-(1 $\alpha$ ,2 $\beta$ ,5 $\alpha$ )-N-[5-methoxy-2-(1-pyrrolidinyl)cyclohexyl]-N-methyl-4-benzofuranacetamide (7).

4-Benzofuranacetic acid (0.757 g, 4.3 mmol) was dissolved in thionyl chloride (3 ml) and heated under reflux for 70 minutes. The resulting solution was concentrated *in vacuo* to furnish an oil which was dissolved in dichloromethane (10 ml), cooled to 0 °C, and treated with a solution of the diamines (4) (0.80 g, 3.8 mmol) in dichloromethane (5 ml). The mixture was stirred at room temperature for 10 minutes and chromatographed on silica gel using 10:1 dichloromethane/methanol to give ( $\pm$ )-(1 $\alpha$ ,2 $\beta$ ,5 $\beta$ )-N-[5-methoxy-2-(1-pyrrolidinyl)cyclohexyl]-N-methyl-4-benzofuranacetamide (6) (150 mg, 0.41 mmol, 11%); i.r. (neat) 1642 cm<sup>-1</sup>; m/e (Cl<sup>+</sup>) 371 (3%); 275 (100%);  $\delta$  (CDCl<sub>3</sub>, 300 MHz) 7.6-6.9 (5H,m); 4.78 (1H,m,C<sub>1</sub>-H); 3.95 (2H,m,CH<sub>2</sub>), 3.56 (m) and 3.46 (m) together are 1H, C<sub>5</sub>-H); 3.33 (s) and 3.13 (s) together are (3H); 2.83 (s) and 2.82 (s) together are (3H), 2.80-1.20 (15H,m). ( $\pm$ )-(1 $\alpha$ ,2 $\beta$ ,4 $\alpha$ )-N-[4-methoxy-2-(1-pyrrolidinyl)cyclohexyl]-N-methyl-4-benzofuranacetamide (5) (100 mg, 0.27 mmol, 7%); i.r. (neat) 1635 cm<sup>-1</sup>; m/e (Cl<sup>+</sup>) 371 (100%);  $\delta$  (CDCl<sub>3</sub>, 300 MHz) 7.55-6.90 (5H,m); 4.60 (1H,dt,J = 12.5 Hz,C<sub>1</sub>-H); 3.95 (2H,m,CH<sub>2</sub>); 3.7-3.4 (1H,m,C<sub>4</sub>-H); 3.29 (s) and 3.24 (s) together are (3H); 3.09 (1H,dt,J = 12.5 Hz,C<sub>2</sub>-H); 2.83 (s) and 2.82 (s) together are (3H); 2.65-1.25 (14H,m). ( $\pm$ )-(1 $\alpha$ ,2 $\beta$ ,5 $\alpha$ )-N-[5-methoxy-2-(1-pyrrolidinyl)cyclohexyl]-N-methyl-4-benzofuranacetamide (7) (92 mg, 0.25 mmol, 7%); i.r. (neat) 1640 cm<sup>-1</sup>; m/e (Cl<sup>+</sup>) 371 (100%), 339 (38%);  $\delta$  - (CDCl<sub>3</sub>, 300 MHz) 7.65-6.85 (5H,m); 4.65 (1H,m,C<sub>1</sub>-H); 3.95 (2H,m,CH<sub>2</sub>); 3.33 (3H,s); 3.70-3.20 (2H,m,C<sub>5</sub>-H and C<sub>2</sub>-H); 2.83 (s) and 2.80 (s) together are (3H); 2.80-0.80 (14H,m).

An analytically pure sample was obtained by treating (6) (100 mg) in diethyl ether (10 ml) with hydrogen chloride. The resulting solution was filtered to give the monohydrochloride salt (100 mg); mp 102-106 °C.

Anal. C<sub>22</sub>H<sub>30</sub>N<sub>2</sub>O<sub>3</sub> · HCl · 0.77 H<sub>2</sub>O requires C, 62.79; H, 7.79; N, 6.66; Cl, 8.42.

Found C, 62.79; H, 7.69; N, 6.64; Cl, 8.20%.

## 30 EXAMPLE 6

( $\pm$ )-(1 $\alpha$ ,2 $\beta$ ,4 $\alpha$ )-N-[4-methoxy-2-(1-pyrrolidinyl)cyclohexyl]-N-methyl-9H-fluorene-9-carboxamide (8) and  
 ( $\pm$ )-(1 $\alpha$ ,2 $\beta$ ,5 $\beta$ )-N-[5-methoxy-2-(1-pyrrolidinyl)cyclohexyl]-N-methyl-9H-fluorene-9-carboxamide (9).

9-Fluorenyl carboxylic acid (210 mg, 1.0 mmol) and pentafluorophenol (184 mg, 1.0 mmol) were dissolved in ethyl acetate (5 ml) and stirred at 0 °C. After five minutes dicyclohexylcarbodiimide (Aldrich Chemical Company) (168 mg, 1.0 mmol) was added and after a further one hour the mixture was treated with the diamines (4) (182 mg, 0.87 mmol) (described above) and allowed to warm to room temperature for one hour. The mixture was filtered and chromatographed on silica gel using 20:1 dichloromethane-methanol to give (8) (33.4 mg, 0.083 mmol, 10%); i.r. (neat) 1632 cm<sup>-1</sup>;  $\delta$  (CDCl<sub>3</sub>, NaOD) 7.80-7.20 (8H,m); 4.57 (1H,dt,J = 13.5 Hz,C<sub>1</sub>-H); 3.25 (3H,s); 3.60-1.20 (19H,m); m/e (El<sup>+</sup>) 404 (0.5%), 389 (2%), 373 (3%), 110 (100%). (9) (34 mg, 0.084 mmol, 10%); i.r. (neat) 1633 cm<sup>-1</sup>;  $\delta$  (CDCl<sub>3</sub>, NaOD) 7.80-7.20 (8H,m); 4.75 (1H,m,C<sub>1</sub>-H); 3.32 (3H,s); 3.60-1.20 (19H,m).

45

## EXAMPLE 7

( $\pm$ )-(1 $\alpha$ ,2 $\beta$ ,4 $\beta$ )-N-[4-methoxy-2-(1-pyrrolidinyl)cyclohexyl]-N-methyl-4-benzofuranacetamide (10)

(10) was prepared from the epoxides (1) by an analogous procedure to that described above for (5), (6),  
 50 and (7) except that pyrrolidine was used instead of N-benzylmethylamine and vice versa. The epoxides (1) (2.0 g, 16 mmol) and pyrrolidine (2.0 g, 28 mmol) were heated to 65 °C for 19 hours then concentrated *in vacuo* to give an oil (3.0 g) which was dissolved in dichloromethane (30 ml) and treated with triethylamine (2.5 ml, 18 mmol) and methanesulphonyl chloride (1.28 ml, 16.5 mmol) at 0 °C for 1.5 hours. The mixture was added to dichloromethane (70 ml) and washed with water (3 x 70 ml), dried (MgSO<sub>4</sub>), and evaporated  
 55 *in vacuo* to give an oil (3.2 g). This oil was dissolved in N-benzylmethylamine (7 ml), heated to 85-90 °C for 1.5 hours, poured into aqueous potassium carbonate, and extracted with dichloromethane (50 ml). Bulb to bulb distillation (oven temperature) 170-225 °C/0.05 mbar, gave a mixture of the diamines (3) (1.1 g, 3.6 mmol, 22%).


This mixture of diamines (3) (1.1 g, 3.6 mmol) was dissolved in ethanol (30 ml) and treated with 20% palladium hydroxide on carbon (0.21 g) and hydrogen at 53 psi and 40°C for five hours to give, as described above, a mixture of the diamines (4) (0.60 g, 2.8 mmol, 78%). This mixture of diamines (0.60 g, 2.8 mmol) was treated with 4-benzofuranacetyl chloride [generated from 4-benzofuranacetic acid (0.6 g, 3.5 mmol) as described above] to give (6) (130 mg, 0.35 mmol, 10%); (5) (25 mg, 0.068 mmol, 2%); and (10) (25 mg, 0.068 mmol, 2%), i.r. (neat) 1635 cm<sup>-1</sup>; m/e (Cl<sup>+</sup>) 371 (67%), 275 (65%), 159 (100%); δ (CDCl<sub>3</sub>, NaOD) 7.65-6.85 (5H,m); 4.55 (1H,br,C<sub>1</sub>-H); 3.95 (2H,m,CH<sub>2</sub>); 3.34 (s) and 3.31 (s) together are (3H); 2.79 (s) and 2.77 (s) together are (3H); 3.60-0.80 (16H,m).

10

## Claims

1. A compound of formula

15



20

wherein the two nitrogen atoms attached to the cyclohexane moiety are trans to one another;

25

X is CH<sub>2</sub> or direct bond,

R<sub>1</sub> is methyl,

R<sub>2</sub> is selected from the group consisting of: hydrogen,  
alkyl of from one to six carbon atoms,

30




35

-CH<sub>2</sub>CH=CR<sub>3</sub>R<sub>4</sub>,

-CH<sub>2</sub>C≡R<sub>3</sub>,

40

-2- or 3-thienyl, or



45

wherein R<sub>3</sub> and R<sub>4</sub> are each independently hydrogen or methyl,

R<sub>5</sub> is selected from the group consisting of:

50

hydrogen,

fluorine,

chlorine,


bromine,

lower alkyl, and

65

lower alkoxy;

or R<sub>1</sub> and R<sub>2</sub> may be taken together with the nitrogen atom to which they are attached to form a ring



5 wherein n is an integer of from 3 to 8; A is selected from the group consisting of:



25 phenyl,  
phenyl substituted with from one to four halogen atoms,  
phenyl substituted with one or two alkyl groups of from one to four carbon atoms,  
phenyl substituted with one or two alkoxy groups of from one to four carbon atoms, or  
30 phenyl substituted with one or two alkyl groups of from one to four carbon atoms and one or two halogen atoms; or  
a pharmaceutically acceptable acid addition salt thereof.

2. A compound according to Claim 1 wherein X is CH<sub>2</sub> and A is



40 3. A compound according to Claim 2 wherein A is




50 4. A compound according to Claim 1 wherein X is a direct bond and A is

55



5

10




5. A compound according to Claim 2 selected from the group consisting of
- (±)-(1 $\alpha$ ,2 $\beta$ ,4 $\beta$ )-N-[4-methoxy-2-(1-pyrrolidinyl) cyclohexyl]-N-methyl-4-benzofuranacetamide,  
 (±)-(1 $\alpha$ ,2 $\beta$ ,4 $\alpha$ )-N-[4-methoxy-2-(1-pyrrolidinyl) cyclohexyl]-N-methyl-4-benzofuranacetamide,  
 (±)-(1 $\alpha$ ,2 $\beta$ ,5 $\beta$ )-N-[5-methoxy-2-(1-pyrrolidinyl) cyclohexyl]-N-methyl-4-benzofuranacetamide, and  
 (±)-(1 $\alpha$ ,2 $\beta$ ,5 $\alpha$ )-N-[5-methoxy-2-(1-pyrrolidinyl) cyclohexyl]-N-methyl-4-benzofuranacetamide.

6. A compound according to Claim 4 selected from the group consisting of
- (±)-(1 $\alpha$ ,2 $\beta$ ,4 $\alpha$ )-N-[4-methoxy-2-(1-pyrrolidinyl) cyclohexyl]-N-methyl-9H-fluorene-9-carboxamide and  
 (±)-(1 $\alpha$ ,2 $\beta$ ,5 $\beta$ )-N-[5-methoxy-2-(1-pyrrolidinyl) cyclohexyl]-N-methyl-9H-fluorene-9-carboxamide.

7. A method of preparing a compound of Claims 1 to 6, wherein A is as defined in Claim 1 which comprises reacting an amine compound of formula

25




30

II

35

wherein R<sub>1</sub> and R<sub>2</sub> are as defined in Claim 1 with A-X-CH<sub>2</sub>COB wherein B is -Cl, -OH, -OC<sub>6</sub>F<sub>5</sub> or

40




and X is CH<sub>2</sub> or a direct bond  
 and, if desired, converting the product to a pharmaceutically acceptable acid addition salt thereof.

45

8. A method of preparing a compound of Claims 1, 2, 3 or 5 wherein A is


50



or


which comprises reacting an amine compound of formula

55




II

10 wherein  $R_1$  and  $R_2$  are as defined in Claim 1 with  $A-X-CH_2COB$  wherein B is -Cl, -OH, -OC<sub>6</sub>F<sub>5</sub> or




20 and X is -CH<sub>2</sub>- or a direct bond  
and, if desired, converting the product to a pharmaceutically acceptable acid addition salt thereof.

9. A method of preparing a compound of Claims 1, 4 or 6 wherein A is




35 which comprises reacting an amine compound of formula




II

45 wherein  $R_1$  and  $R_2$  are as defined in Claim 1 with



wherein B is -OH, -Cl, or



5

or  $\text{OC}_6\text{F}_5$  and, if desired, converting the product to a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising a therapeutically effective amount of a compound as claimed in Claims 1 to 6 together with a pharmaceutically acceptable carrier.

11. Use of a compound of Claims 1 to 6 for the preparation of a pharmaceutical composition for treating stroke or pain in a mammal.

15

20

25

30

35

40

45

50

55



(11) Publication number: **0 372 466 A3**

(12) **EUROPEAN PATENT APPLICATION**

(21) Application number: **89122372.9**

(51) Int. Cl.<sup>5</sup>: **C07D 307/79, C07D 295/135,  
 C07D 333/54, A61K 31/34,  
 A61K 31/38, A61K 31/40**

(22) Date of filing: **05.12.89**

(30) Priority: **06.12.88 US 280759**

(43) Date of publication of application:  
**13.06.90 Bulletin 90/24**

(84) Designated Contracting States:  
**AT BE CH DE ES FR GB IT LI LU NL SE**

(88) Date of deferred publication of the search report:  
**10.04.91 Bulletin 91/15**


(71) Applicant: **WARNER-LAMBERT COMPANY**  
**201 Tabor Road**  
**Morris Plains New Jersey 07950(US)**

(72) Inventor: **Horwell, David Christopher**  
**8, West Hill Foxton**  
**Cambridge(GB)**  
 Inventor: **Rees, David C.**  
**33, Norwich Street**  
**Cambridge CB2 2JB(GB)**

(74) Representative: **Mansmann, Ivo**  
**c/o Gödecke AG - Patentabteilung Postfach**  
**569 Mooswaldallee 1-9**  
**W-7800 Freiburg(DE)**

(54) **2-Amino-4 or 5-methoxycyclohexyl amides useful as analgesics.**

(57) The invention concerns a series of novel 2-amino-monomethoxycyclohexyl amides of the general formula



having analgesic and neuroprotective activity. The compounds bind selectively to the kappa opioid receptor. Pharmaceutical compositions containing the compounds, methods of using them, and processes for preparing them are also disclosed.



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number

DOCUMENTS CONSIDERED TO BE RELEVANT			EP 89122372.9
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
X	<u>FR - A - 2 503 702</u> (UPJOHN) * Formula XXIV; example 1E * --	1	C 07 D 307/79 C 07 D 295/135 C 07 D 333/54 C 07 D 405/12
P,A	<u>US - A - 4 855 316</u> (HORWELL) * Formula I; claims 1,15,16 * --	1, 10, 11	C 07 C 233/41 C 07 C 233/79 A 61 K 31/34 A 61 K 31/38 A 61 K 31/40
A	<u>EP - A1 - 0 260 555</u> (DU PONT) * Example 3; claims 12,13 * --	1, 10, 11	
D,A	<u>US - A - 4 598 087</u> (HORWELL) * Claims 1,5,6 * --		
D,A	<u>US - A - 4 460 600</u> (KAPLAN) * Claims 1,10 * --	1, 10	
D,A	<u>US - A - 4 677 122</u> (HORWELL) * Claims 1,3,4 * --	1, 10, 11	TECHNICAL FIELDS SEARCHED (Int. Cl.5)
P,A	CHEMICAL ABSTRACTS, vol. 111, no. 7, August 14, 1989, Columbus, Ohio, USA HALFPENNY, PAUL R. et al. "Highly selective k-opioid analgesics. 2. Synthesis and structure activity relationships of novel N- (2-aminocyclohexyl)arylace- tamide derivatives" page 734, column 1, abstract -No. 57 465v & J. Med. Chem. 1989, 32(7), 1620-6 ----	1, 11	C 07 D 307/00 C 07 D 295/00 C 07 D 333/00 C 07 D 405/00
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
VIENNA	01-02-1991	HAMMER	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

11 x 2

11 x 2

**THIS PAGE BLANK (USPTO)**